About oruka therapeutics - ORKA
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
ORKA At a Glance
Oruka Therapeutics, Inc.
855 Oak Grove Avenue
Menlo Park, California 94025
| Phone | 1-650-606-7910 | Revenue | 0.00 | |
| Industry | Miscellaneous Commercial Services | Net Income | -5,339,000.00 | |
| Sector | Commercial Services | Employees | 5 | |
| Fiscal Year-end | 12 / 2024 | |||
| View SEC Filings |
ORKA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.666 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 1.76 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.022 |
ORKA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,067,800.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
ORKA Liquidity
| Current Ratio | 59.014 |
| Quick Ratio | 59.014 |
| Cash Ratio | 58.761 |
ORKA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -13.192 |
| Return on Equity | -13.569 |
| Return on Total Capital | -14.314 |
| Return on Invested Capital | -13.486 |
ORKA Capital Structure
| Total Debt to Total Equity | 0.756 |
| Total Debt to Total Capital | 0.751 |
| Total Debt to Total Assets | 0.74 |
| Long-Term Debt to Equity | 0.551 |
| Long-Term Debt to Total Capital | 0.547 |